TY  - GEN
AU  - Gerding,Dale N
AU  - Kelly,Ciaran P
AU  - Rahav,Galia
AU  - Lee,Christine
AU  - Dubberke,Erik R
AU  - Kumar,Princy N
AU  - Yacyshyn,Bruce
AU  - Kao,Dina
AU  - Eves,Karen
AU  - Ellison,Misoo C
AU  - Hanson,Mary E
AU  - Guris,Dalya
AU  - Dorr,Mary Beth
TI  - Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence
SN  - 1537-6591
PY  - 2019///1024
KW  - Adolescent
KW  - Adult
KW  - Age Factors
KW  - Aged
KW  - Aged, 80 and over
KW  - Anti-Bacterial Agents
KW  - therapeutic use
KW  - Antibodies, Monoclonal
KW  - Antibodies, Neutralizing
KW  - Broadly Neutralizing Antibodies
KW  - Clostridioides difficile
KW  - drug effects
KW  - Clostridium Infections
KW  - mortality
KW  - Fecal Microbiota Transplantation
KW  - Female
KW  - Fidaxomicin
KW  - administration & dosage
KW  - Humans
KW  - Male
KW  - Metronidazole
KW  - Middle Aged
KW  - Patient Readmission
KW  - Recurrence
KW  - Risk Factors
KW  - Secondary Prevention
KW  - Vancomycin
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1093/cid/ciy171
ER  -